Avidity Biosciences announced encouraging early and mid-stage trial results for del-zota, an antibody-oligonucleotide conjugate addressing Duchenne muscular dystrophy (DMD). Patients treated continuously for a year showed reversal of disease progression and functional improvements. Concurrently, Remynd NV revealed positive phase IIa data for REM-127, targeting Alzheimer’s disease by restoring neuronal calcium homeostasis, reducing pathological tau proteins and enhancing cognition. These developments mark potentially significant advancements in treatment options for these challenging conditions.